STIM Neuronetics

Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call

Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter 2020 financial and operating results prior to market open on Tuesday, August 4, 2020. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The call will be concurrently webcast.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at . To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 9783274, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.  NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at .  

Investor Contact:

Mark R. Klausner

Westwicke Partners

443-213-0501

Media Contact:

Gina Kent

Vault Communications

610-455-2763

EN
21/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics Comments on Letter from Pointillist Family Office

Neuronetics Comments on Letter from Pointillist Family Office MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026: The Board and management team are...

 PRESS RELEASE

Neuronetics Announces Chief Financial Officer Transition

Neuronetics Announces Chief Financial Officer Transition Reaffirms Fiscal Year 2026 Financial Guidance MALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company....

 PRESS RELEASE

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Op...

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; pr...

 PRESS RELEASE

Neuronetics Appoints Dan Reuvers as President and Chief Executive Offi...

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today an...

 PRESS RELEASE

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Resu...

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch